Hugel, Inc. (145020.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩179,400 (+1.70%) as of
Key statistics
- Market cap
- 1.94T
- Forward P/E
- 11.34
- Dividend yield
- 0.00%
- 52-week range
- 163,700.00 – 308,500.00
- Beta
- 0.56
- Revenue (TTM)
- 479.57B
- Profit margin
- 32.94%
- Analyst target
- ₩298,647.06
- Volume
- 40.39k
About Hugel, Inc.
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Chuncheon-si, South Korea
- Employees
- 620
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.